Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis

P. Colombatto, F. Oliveri, G. Leandro, M. Baldi, M. Capalbo, G. Rocca, M. R. Brunetto, F. Bonino

Research output: Contribution to journalArticle

Abstract

Background. Platelet and white blood cell counts decrease in chronic viral hepatitis patients treated with alpha interferon. Aims. To analyse whether delta negative variations in platelets and white blood cells are influenced by type, dose and duration of alpha interferon treatment, we studied 340 consecutive patients (mean treatment 8 months, range 4-18 months). Patients and methods. A total of 204 (60%) patients were treated with recombinant alpha interferons (30% alpha-2a and 30% alpha-2b), 64 (19%) with N3.leukocytic and 72 (21%) N1.lymphoblastoid natural interferons. Median age and male-female ratios were comparable in the 3 groups (41, 41 and 43 years and 2.3, 2.6 and 2.5, respectively). The lowest platelets and white blood cells counts were observed between the 2nd and the 4th month of therapy in all patients. Age, sex, aetiology and durations of interferon therapy did not influence the platelets and white blood cells reduction rates. The decrease was lower for patients treated with N3.leukocytic interferon than for the other interferons. A significant difference was observed between interferon doses when the groups treated with 3 or 9-10 MIU were compared. However, dose or cirrhosis-related bias are ruled out by similar proportions of cirrhosis and patients treated with 3 MIU in the 3 groups of patients treated with different types of interferon. Conclusions. The type of interferon appears to represent a major cause of the different haemopoietic toxicity. The lowest toxicity of N3.leukocytic interferon may have clinical implications for the choice of interferon in patients with low baseline platelets and white blood cells counts. These findings prompt prospective studies on larger series of patients.

Original languageEnglish
Pages (from-to)441-447
Number of pages7
JournalItalian Journal of Gastroenterology and Hepatology
Volume29
Issue number5
Publication statusPublished - 1997

Fingerprint

Chronic Hepatitis
Leukocyte Count
Interferon-alpha
Blood Platelets
Interferons
Therapeutics
Leukocytes
Fibrosis
Prospective Studies

Keywords

  • Alpha interferon
  • Chronic viral hepatitis
  • Platelets
  • White blood cells

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis. / Colombatto, P.; Oliveri, F.; Leandro, G.; Baldi, M.; Capalbo, M.; Rocca, G.; Brunetto, M. R.; Bonino, F.

In: Italian Journal of Gastroenterology and Hepatology, Vol. 29, No. 5, 1997, p. 441-447.

Research output: Contribution to journalArticle

Colombatto, P. ; Oliveri, F. ; Leandro, G. ; Baldi, M. ; Capalbo, M. ; Rocca, G. ; Brunetto, M. R. ; Bonino, F. / Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis. In: Italian Journal of Gastroenterology and Hepatology. 1997 ; Vol. 29, No. 5. pp. 441-447.
@article{f19fd22e85bb4421a482533222f05a07,
title = "Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis",
abstract = "Background. Platelet and white blood cell counts decrease in chronic viral hepatitis patients treated with alpha interferon. Aims. To analyse whether delta negative variations in platelets and white blood cells are influenced by type, dose and duration of alpha interferon treatment, we studied 340 consecutive patients (mean treatment 8 months, range 4-18 months). Patients and methods. A total of 204 (60{\%}) patients were treated with recombinant alpha interferons (30{\%} alpha-2a and 30{\%} alpha-2b), 64 (19{\%}) with N3.leukocytic and 72 (21{\%}) N1.lymphoblastoid natural interferons. Median age and male-female ratios were comparable in the 3 groups (41, 41 and 43 years and 2.3, 2.6 and 2.5, respectively). The lowest platelets and white blood cells counts were observed between the 2nd and the 4th month of therapy in all patients. Age, sex, aetiology and durations of interferon therapy did not influence the platelets and white blood cells reduction rates. The decrease was lower for patients treated with N3.leukocytic interferon than for the other interferons. A significant difference was observed between interferon doses when the groups treated with 3 or 9-10 MIU were compared. However, dose or cirrhosis-related bias are ruled out by similar proportions of cirrhosis and patients treated with 3 MIU in the 3 groups of patients treated with different types of interferon. Conclusions. The type of interferon appears to represent a major cause of the different haemopoietic toxicity. The lowest toxicity of N3.leukocytic interferon may have clinical implications for the choice of interferon in patients with low baseline platelets and white blood cells counts. These findings prompt prospective studies on larger series of patients.",
keywords = "Alpha interferon, Chronic viral hepatitis, Platelets, White blood cells",
author = "P. Colombatto and F. Oliveri and G. Leandro and M. Baldi and M. Capalbo and G. Rocca and Brunetto, {M. R.} and F. Bonino",
year = "1997",
language = "English",
volume = "29",
pages = "441--447",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis

AU - Colombatto, P.

AU - Oliveri, F.

AU - Leandro, G.

AU - Baldi, M.

AU - Capalbo, M.

AU - Rocca, G.

AU - Brunetto, M. R.

AU - Bonino, F.

PY - 1997

Y1 - 1997

N2 - Background. Platelet and white blood cell counts decrease in chronic viral hepatitis patients treated with alpha interferon. Aims. To analyse whether delta negative variations in platelets and white blood cells are influenced by type, dose and duration of alpha interferon treatment, we studied 340 consecutive patients (mean treatment 8 months, range 4-18 months). Patients and methods. A total of 204 (60%) patients were treated with recombinant alpha interferons (30% alpha-2a and 30% alpha-2b), 64 (19%) with N3.leukocytic and 72 (21%) N1.lymphoblastoid natural interferons. Median age and male-female ratios were comparable in the 3 groups (41, 41 and 43 years and 2.3, 2.6 and 2.5, respectively). The lowest platelets and white blood cells counts were observed between the 2nd and the 4th month of therapy in all patients. Age, sex, aetiology and durations of interferon therapy did not influence the platelets and white blood cells reduction rates. The decrease was lower for patients treated with N3.leukocytic interferon than for the other interferons. A significant difference was observed between interferon doses when the groups treated with 3 or 9-10 MIU were compared. However, dose or cirrhosis-related bias are ruled out by similar proportions of cirrhosis and patients treated with 3 MIU in the 3 groups of patients treated with different types of interferon. Conclusions. The type of interferon appears to represent a major cause of the different haemopoietic toxicity. The lowest toxicity of N3.leukocytic interferon may have clinical implications for the choice of interferon in patients with low baseline platelets and white blood cells counts. These findings prompt prospective studies on larger series of patients.

AB - Background. Platelet and white blood cell counts decrease in chronic viral hepatitis patients treated with alpha interferon. Aims. To analyse whether delta negative variations in platelets and white blood cells are influenced by type, dose and duration of alpha interferon treatment, we studied 340 consecutive patients (mean treatment 8 months, range 4-18 months). Patients and methods. A total of 204 (60%) patients were treated with recombinant alpha interferons (30% alpha-2a and 30% alpha-2b), 64 (19%) with N3.leukocytic and 72 (21%) N1.lymphoblastoid natural interferons. Median age and male-female ratios were comparable in the 3 groups (41, 41 and 43 years and 2.3, 2.6 and 2.5, respectively). The lowest platelets and white blood cells counts were observed between the 2nd and the 4th month of therapy in all patients. Age, sex, aetiology and durations of interferon therapy did not influence the platelets and white blood cells reduction rates. The decrease was lower for patients treated with N3.leukocytic interferon than for the other interferons. A significant difference was observed between interferon doses when the groups treated with 3 or 9-10 MIU were compared. However, dose or cirrhosis-related bias are ruled out by similar proportions of cirrhosis and patients treated with 3 MIU in the 3 groups of patients treated with different types of interferon. Conclusions. The type of interferon appears to represent a major cause of the different haemopoietic toxicity. The lowest toxicity of N3.leukocytic interferon may have clinical implications for the choice of interferon in patients with low baseline platelets and white blood cells counts. These findings prompt prospective studies on larger series of patients.

KW - Alpha interferon

KW - Chronic viral hepatitis

KW - Platelets

KW - White blood cells

UR - http://www.scopus.com/inward/record.url?scp=0031406860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031406860&partnerID=8YFLogxK

M3 - Article

C2 - 9494854

AN - SCOPUS:0031406860

VL - 29

SP - 441

EP - 447

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 5

ER -